Login

Keenova Therapeutics plc

mallinckrodt.com

What Do They Do?

Develops and sells branded medicines for rare or unaddressed conditions to healthcare providers and hospitals, often through medicine distributors.

Who Are Their Customers?

The company markets products to physicians and other healthcare providers; pharmacies, hospitals and institutions buy directly in some cases, while other sales go through wholesalers and specialty distributors. It also contracts with payer groups to set product pricing and support access.

Customers above 10% of revenue, FY2025
of revenue from two customers (46%, 12%)
FY2024: 42% from one customer

Do Revenues Turn Into Profits?

Not on paper. It lost $489.5M in FY2025, but brought in more cash than it spent: $142.1M of free cash flow.

Operating income, FY2025
−24% of revenue
▼ −428% (Loss) vs FY2024 (−$65.9M, −6%)
Net income, FY2025
−34% of revenue
▼ Turned to a loss vs FY2024 ($477.9M, 44%)
Free cash flow, FY2025
10% of revenue
▲ +34% vs FY2024 ($105.9M, 10%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +32%
vs $416.1M in Q3 FY2025
Net income
▲ +67% (Loss)
vs −$291.1M in Q3 FY2025
  • Aug 11, 2026 Raises Acthar sales outlook and tightens Xiaflex growth outlook Acthar sales growth guidance is 20%-22%; Xiaflex growth guidance is high single-digits.
  • Aug 3, 2026 Completes sale of Percocet and Endocet businesses After transition services are complete, Keenova will no longer market, manufacture or distribute opioid products.

Branded focus The older report described branded specialty medicines alongside specialty generics and active pharmaceutical ingredients. The latest report centers the business on branded therapeutics after separating its generic pharmaceuticals and sterile injectables businesses into Par Health.

Revenue over time
Acthar Gel Xiaflex INOmax Therakos Amitiza Other Product Sales License
$2B$1B$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support